HER2 inhibition: From discovery to clinical practice

被引：41
作者：
Chang, Jenny C. [1 ]
机构：
[1] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 01期
关键词：
D O I：
10.1158/1078-0432.CCR-06-2405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 50 条
  • [31] The Clinical Importance of the Heterogeneity of HER2 neu
    Davila, Enrique
    Amazon, Kip
    CASE REPORTS IN ONCOLOGY, 2010, 3 (02): : 268 - 271
  • [32] The clinical significance of HER2 expression in DCIS
    Akrida, Ioanna
    Mulita, Francesk
    MEDICAL ONCOLOGY, 2022, 40 (01)
  • [33] A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
    Dressler, LG
    Broadwater, G
    Berry, D
    Cirrincione, C
    Cowan, D
    Harris, L
    Moore, D
    Muss, H
    Hayes, D
    Ellis, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 18S - 18S
  • [34] HER2 Biology, Detection, and Clinical Implications
    Gutierrez, Carolina
    Schiff, Rachel
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (01) : 55 - 62
  • [35] HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
    Tse, Chantal
    Gauchez, Anne-Sophie
    Jacot, William
    Lamy, Pierre-Jean
    CANCER TREATMENT REVIEWS, 2012, 38 (02) : 133 - 142
  • [36] The clinical significance of HER2 expression in DCIS
    Ioanna Akrida
    Francesk Mulita
    Medical Oncology, 40
  • [37] Modeling HER2 Inhibition in Breast Cancer Cells
    Fink, Marc Y.
    Zhou, Danni
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 614A - 614A
  • [38] Unraveling the Biologic and Clinical Complexities of HER2
    Park, John W.
    Neve, Richard A.
    Szollosi, Janos
    Benz, Christopher C.
    CLINICAL BREAST CANCER, 2008, 8 (05) : 392 - 401
  • [39] SOS1 inhibition in combination with HER2 inhibition in models of HER2driven cancer
    Schenk, Robyn L.
    Kostyrko, Kaja
    Popow, Johannes
    Gewinner, Christina
    Baum, Anke
    Albrecht, Christoph
    Hinkel, Melanie
    Jacob, Robin
    Madensky, Tom
    Ruzicka, Regina
    Strauss, Eva
    Lyu, Hengyu
    Lopez, Anastasia M.
    Feng, Ningping
    Vellano, Christopher P.
    Marszalek, Joseph R.
    Heffernan, Timothy P.
    Pearson, Mark
    Hofmann, Marco H.
    CANCER RESEARCH, 2024, 84 (06)
  • [40] Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
    Li, Yujue
    Li, Jiaxuan
    Zhou, Haoxuan
    Liu, Chengyali
    Liu, Zi
    Ying, Binwu
    Xie, Yongmei
    Hu, Mingxing
    Gong, Youling
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 244
12345